Share chart Annexon, Inc.
Extended chart
Simple chart
About
Annexon, Inc., биофармацевтическая компания, работающая на клинической стадии, открывает и разрабатывает лекарственные средства для лечения аутоиммунных и нейродегенеративных заболеваний. Он специализируется на лечении заболеваний тела, головного мозга и глаз. C1q компании является инициирующей молекулой классического пути комплемента, который нацелен на различные болезненные процессы, такие как опосредованное антителами аутоиммунное заболевание и опосредованная комплементом нейродегенерация. more details| IPO date | 2020-07-24 |
|---|---|
| ISIN | US03589W1027 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.annexonbio.com |
| Цена ао | 4.83 |
| Change price per day: | 0% (4.83) |
|---|---|
| Change price per week: | -4.36% (5.05) |
| Change price per month: | +7.1% (4.51) |
| Change price per 3 month: | -34.82% (7.41) |
| Change price per half year: | -17.72% (5.87) |
| Change price per year: | +15% (4.2) |
| Change price per 3 year: | -40.52% (8.12) |
| Change price per 5 year: | 0% (4.83) |
| Change price per 10 year: | 0% (4.83) |
| Change price per year to date: | -8.52% (5.28) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| FMR, LLC | 9685401 | 12.36 |
| Bain Capital Life Sciences Investors, LLC | 8061719 | 10.29 |
| Alerce Investment Management, L.P. | 7406024 | 9.45 |
| BVF Inc. | 7000000 | 8.93 |
| Redmile Group, LLC | 5503190 | 7.02 |
| Adage Capital Partners GP L.L.C. | 4999975 | 6.38 |
| Logos Global Management LP | 4950000 | 6.32 |
| Blackrock Inc. | 3318579 | 4.23 |
| GMT Capital Corp | 3020474 | 3.85 |
| Ikarian Capital, LLC | 2650000 | 3.38 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| iShares Neuroscience and Healthcare ETF | 1.10026 | 19.72 | 0.03 |
| Virtus LifeSci Biotech Clinical Trials ETF | 0.92658 | 63.04 | 0.33 |
| iShares Micro-Cap ETF | 0.17043 | 13.79 | 1.54048 |
| Vanguard U.S. Momentum Factor ETF | 0.11 | 27.18 | 1.05834 |
| Avantis U.S Small Cap Equity ETF | 0.06779 | 27.77 | 1.68271 |
| Goldman Sachs ActiveBeta US Small Cap Equity ETF | 0.02663 | 31.36 | 1.41955 |
| Vanguard Russell 2000 ETF | 0.02 | 14.37 | 1.48801 |
ProShares UltraPro Russell2000
|
0.01279 | 89.82 | 1.47873 |
| Dimensional U.S. Core Equity 2 ETF | 0.00546 | 30.76 | 1.47098 |
| ProShares Hedge Replication ETF | 0.00355 | 5.92 | 1.47892 |
| Dimensional US Core Equity Market ETF | 0.00144 | 30.98 | 1.40618 |
| iShares Russell 3000 ETF | 0.00111 | 23.61 | 1.43482 |
| Dimensional U.S. Equity ETF | 0.00089 | 31.53 | 1.3557 |
| Avantis U.S. Equity ETF | 0.00038 | 20.45 | 1.59151 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Ted Yednock Ph.D. | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 614.6k | 1958 (67 years) |
| Ms. Jennifer Lew | Executive VP, CFO & Corporate Secretary | 624.2k | 1973 (52 years) |
| Mr. Douglas Love Esq., J.D. | CEO, President & Director | 921.99k | 1968 (57 years) |
| Dr. Jamie Dananberg M.D. | Executive VP & Chief Medical Officer | N/A | 1958 (67 years) |
| Dr. Dean R. Artis Ph.D. | Chief Scientific Officer & Executive VP | 1961 (64 years) | |
| Mr. Michael Overdorf M.B.A. | Executive VP & Chief Business Officer | 1971 (54 years) | |
| Mr. Henk-Andre Kroon M.D. | Senior Vice President of Translational Medicine | ||
| Mr. Shikhar Agarwal M.B.A. | Senior VP & Head of Commercial | ||
| Dr. Sunil Mehta Pharm.D. | Senior VP of Medical Affairs |
Address: United States, South San Francisco, CA , 180 Kimball Way - open in Google maps, open in Yandex maps
Website: https://www.annexonbio.com
Website: https://www.annexonbio.com
